Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 3/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.41 |
| ▸ | FABP3 | P05413 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15375348 | 0.87 | TSHR (0.37) | PTGDR2LPAR1KDM4EMRGPRX4HDAC8 | |
| SCHEMBL15401433 | 0.87 | LPAR1 (0.45) | PTGDR2LPAR1FABP4FABP5FABP3 | |
| SCHEMBL15402040 | 0.87 | PTGDR2 (0.53) | PTGDR2KDM4EFABP4FABP5FABP3 | |
| SCHEMBL15402016 | 0.87 | PTGDR2 (0.50) | PTGDR2KDM4EFABP4FABP5FABP3 | |
| SCHEMBL15375554 | 0.86 | FABP4 (0.44) | KDM4EFABP4FABP5MEN1KMT2A | |
| SCHEMBL15375528 | 0.86 | LPAR1 (0.42) | PTGDR2LPAR1FABP4FABP5FABP3 | |
| SCHEMBL15375481 | 0.80 | FABP4 (0.37) | LPAR1KDM4EFABP4FABP5MEN1 | |
| SCHEMBL15375550 | 0.80 | SGMS2 (0.41) | PTGDR2LPAR1FABP4FABP5MRGPRX4 | |
| SCHEMBL15401875 | 0.79 | PTGDR2 (0.49) | PTGDR2MRGPRX4MEN1KMT2A | |
| SCHEMBL15402168 | 0.78 | KDM4E (0.41) | PTGDR2KDM4EFABP4FABP5FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103588657-B | The manufacture method of phenylacetyl amines | 住友化学株式会社 | 2016-06-22 | — | — | CN | disclosed |
| EP-2397459-B1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-8624062-B2 | Method for producing phenylacetamide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20110295035-A1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110295035-A1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | MRPL21, AADAC, ARSA | PTGDR2 938/4885LPAR1 3283/4885KDM4E 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.